Skip Navigation


NDT Advance Access originally published online on September 12, 2006
Nephrology Dialysis Transplantation 2006 21(11):3005-3006; doi:10.1093/ndt/gfl505
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/11/3005    most recent
gfl505v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in NDT
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tonelli, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tonelli, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Do statins protect the kidney as well as the heart?

Marcello Tonelli

Department of Medicine, University of Alberta, Department of Critical Care, University of Alberta, Institute of Health Economics and Department of Public Health Sciences, University of Alberta, Edmonton, Canada

Correspondence and offprint requests to: Dr Tonelli, 7-129 Clinical Sciences Building, 8440-112 Street, Edmonton, Alberta T6G 2G3, Canada. Email: mtonelli@ualberta.ca

Keywords: statins; CKD; PREVEND study

The first 10% of the full text of this article appears below.

Statins are widely prescribed for the prevention of vascular disease, based on a large body of evidence showing that they reduce mortality and the risk of vascular events [1]. The idea that dyslipidaemia might promote progressive kidney disease was first advanced more than 100 years ago [2], and is supported by experimental and clinical evidence [3]. It has been suggested that lipid-modifying treatment reduces proteinuria and prevents kidney function loss—especially statins that have been the most extensively studied class of agent for this indication.

A recent systematic review of 27 randomized trials (with a total of 39 704 participants) suggested that statins reduce the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in NDT:

The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study
Jarir Atthobari, Auke H. Brantsma, Ron T. Gansevoort, Sipke T. Visser, Folkert W. Asselbergs, Wiek H. van Gilst, Paul E. de Jong, Lolkje T. W. de Jong-van den Berg, and on behalf of PREVEND study group
NDT 2006 21: 3106-3114. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
E. Ritz and C. Wanner
Lipid Abnormalities and Cardiovascular Risk in Renal Disease
J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1065 - 1070.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
Y. Furumatsu, Y. Nagasawa, T. Hamano, H. Iwatani, K. Iio, T. Shoji, T. Ito, Y. Tsubakihara, and E. Imai
Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan
Nephrol. Dial. Transplant., March 1, 2008; 23(3): 984 - 990.
[Abstract] [Full Text] [PDF]